DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2009/0311321 A1 Mimura Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2009/0311321 A1 Mimura Et Al US 20090311321A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0311321 A1 Mimura et al. (43) Pub. Date: Dec. 17, 2009 (54) ORAL DISINTEGRATING TABLET HAVING (30) Foreign Application Priority Data MLASKED BITTERTASTE AND METHOD FOR PRODUCTION THEREOF Aug. 8, 2006 (JP) ................................. 2006-215146 (75) Inventors: Kazuki Mimura, Nagano (JP); Publication Classification Yasuhiro Takeda, Nagano (JP); (51) Int. Cl. Ken Kanada, Nagano (JP) A69/20 (2006.01) Correspondence Address: A63L/403 (2006.01) SUGHRUE MION, PLLC (52) U.S. Cl. ......................................... 424/465; 514/412 2100 PENNSYLVANIA AVENUE, N.W., SUITE 8OO (57) ABSTRACT WASHINGTON, DC 20037 (US) The present invention provides an orally disintegrating tablet containing mitiglinide calcium hydrate. The tablet has (73) Assignee: KISSE PHARMACEUTICAL reduced bitterness and quickly disintegrates in the mouth, CO.,LTD., Matsumoto-shi (JP) while exhibiting rapid dissolution in the digestive tract. The bitterness-masked orally disintegrating tablet comprises: (a) (21) Appl. No.: 12/376,161 mitiglinide calcium hydrate; (b) microcrystalline cellulose; (c) at least one masking agent selected from the group con (22) PCT Fled: Aug. 3, 2007 sisting of aminoalkyl methacrylate copolymer E. polyviny (86) PCT NO.: PCT/UP2007/065228 lacetal diethylaminoacetate, an ethyl acrylate-methyl meth acrylate copolymer, and ethyl cellulose; (d) a Sugar or a Sugar S371 (c)(1), alcohol; and (e) at least one selected from corn starch and (2), (4) Date: Feb. 3, 2009 partially pregelatinized starch. US 2009/03 11321 A1 Dec. 17, 2009 ORAL DISINTEGRATING TABLET HAVING 0012 Patent literature 5: A pamphlet of International Pub MLASKED BITTERTASTE AND METHOD lication 2002/002083 FOR PRODUCTION THEREOF DISCLOSURE OF THE INVENTION TECHNICAL FIELD 0013 The inventors of the present invention conducted studies on orally disintegrating tablets containing mitiglinide 0001. The present invention relates to a bitterness-masked calcium hydrate. The studies found that mitiglinide calcium orally disintegrating tablet containing mitiglinide calcium hydrate produces a strong bitter taste during administration. hydrate, and a method for preparing Such tablets. Because the orally disintegrating tablets are designed to quickly disintegrate in the mouth, the influence of bitterness BACKGROUND ART becomes a big factor when the active ingredient has a bitter taste. It was also found that, because the mitiglinide calcium 0002 Mitiglinide calcium hydrate (chemical name: (+)- hydrate does not easily dissolve in water, simply disintegrat Monocalcium bis(2S,3a,7a-cis)-O-benzylhexahydro-y-oxo ing the tablet in the mouth is not sufficient to rapidly dissolve 2-isoindolinebutyratedihydrate) has an activity to improve the compound in the digestive tract. Under these circum stances, the inventors of the present invention conducted stud postprandial hyperglycemia in type-2 diabetes mellitus. The ies to provide a mitiglinide calcium hydrate-containing orally mechanism of action involves binding to the Sulfonylurea disintegrating tablet having reduced bitterness and capable of receptors of the pancreatic B cells to inhibit ATP-dependent rapidly dissolving in the digestive tract. K" channel currents and thereby promoting insulin secretion 0014 Various methods have been proposed to reduce bit (see Non-Patent Document 1, for example). terness, using, for example, a flavoring agentoragel-forming 0003 Mitiglinide calcium hydrate is commercially avail anionic polymer (see Patent Document 3, for example), and a able as a tablet preparation, intended for oral administration water-insoluble polymer (see Patent Document 4, for in a single dose of 5 to 20 mg for adults, three times a day. example). The inventors of the present invention applied Mitiglinide calcium hydrate is taken immediately before each these techniques to mitiglinide calcium hydrate. However, a meal, or more preferably within 5 minutes before meal, sufficient masking effect could not be obtained with the addi because absorption is slow and the efficacy attenuates in tion of a flavoring agent or a gel-forming anionic polymer. postprandial administration. In order to provide an insulin Adding a water-insoluble substance reduced bitterness, but secretagogue capable of quickly exhibiting its action after the dissolution of the drug was delayed in this case. A method administration, there have been developments of mitiglinide is proposed in which the masking effect is provided by spray calcium hydrate-containing preparations that can rapidly dis drying a mixture of a bitter drug and an insoluble polymer (see Patent Document 5, for example). However, this tech Solve in the digestive tract. nique is not applicable to mitiglinide calcium hydrate, 0004. There have also been developments of solid prepa because of the strong water repellency of mitiglinide calcium rations that can quickly disintegrate or dissolve in the mouth, hydrate. in an effort to provide a dosage form readily administrable to 0015 The inventors of the present invention further con the elderly, children, and patients having a problem with ducted intensive studies on orally disintegrating tablets using Swallowing, or a dosage form that does not require water for a water-insoluble Substance as a masking agent. As a result, it administration. was found that an orally disintegrating tablet having consid 0005 WO2003/61650 discloses an orally disintegrating erably reduced bitterness and capable of rapidly dissolving in tablet containing (a) mitiglinide calcium hydrate, and (b) the digestive tract can be obtained when it includes a granu granules of co-spray dried lactose and starch (see Patent lated material formed from mitiglinide calcium hydrate, Document 1, for example). However, WO2003/61650 does microcrystalline cellulose, and a water-insoluble Substance. The inventors of the present invention also found that an not disclose anything about a bitterness-masked orally disin orally disintegrating tablet having an appropriate hardness tegrating tablet of mitiglinide calcium hydrate. and capable of quickly disintegrating in the mouth can be 0006 WO00/71117 discloses an immediate-release obtained when it is prepared from Such a mitiglinide calcium medicinal composition for oral use, containing mitiglinide hydrate-containing granulated material, a Sugar or a Sugar calcium hydrate as an active ingredient (see Patent Document alcohol, and at least one selected from corn starch and par 2, for example). However, the medicinal composition dis tially pregelatinized starch. The present invention was closed in WO00771117 is an immediate-release tablet for the accomplished based on these findings. digestive tract such as the stomach, and the publication does 0016 Specifically, the present invention provides: not disclose anything about tablets that can quickly disinte grate in the mouth, nor does it disclose bitterness-masked 0017. 1 a bitterness-masked orally disintegrating tablet, orally disintegrating tablets. comprising: (a) mitiglinide calcium hydrate as a bitter active ingredient; 0007. Non-Patent literature 1: Ohnota H. et al., J. Phar (b) microcrystalline cellulose; macol. Exp. Then, 1994, vol. 269, p. 489-495 (c) at least one masking agent selected from the group con 0008 Patent literature 1: A pamphlet of International Pub sisting of aminoalkyl methacrylate copolymer E. polyviny lication 2003/61650 lacetal diethylaminoacetate, an ethyl acrylate-methyl meth 0009 Patent literature 2: A pamphlet of International Pub acrylate copolymer, and ethyl cellulose; lication 2000771117 (d) a Sugar or a Sugar alcohol; and 0010 Patent literature 3: JP-A-4-235.136 (e) at least one selected from corn starch and partially prege 0011 Patent literature 4: JP-A-2004-339071 latinized starch; US 2009/03 11321 A1 Dec. 17, 2009 0018 2 a bitterness-masked orally disintegrating tablet, soluble acrylic polymer. Examples of the stomach-soluble comprising: polymer include methyl methacrylate-butyl methacrylate a granulated material including: dimethylaminoethyl methacrylate copolymers such as ami (a) mitiglinide calcium hydrate as a bitter active ingredient; noalkyl methacrylate copolymer E (For example, Eudragit (b) microcrystalline cellulose; and EPO, Roehm Pharma Gmbh: Eudragit E100, Roehm Pharma (c) at least one masking agent selected from the group con Gmbh), and stomach-soluble polyvinyl derivatives such as sisting of aminoalkyl methacrylate copolymer E. polyviny polyvinylacetal diethylaminoacetate (for example, AEA, lacetal diethylaminoacetate, an ethyl acrylate-methyl meth Sankyo). Examples of the water-insoluble cellulose ether acrylate copolymer, and ethyl cellulose; include ethyl celluloses (for example, Ethocel STD10FP. (d) a Sugar or a Sugar alcohol; and Dow Chemical Company), and aqueous dispersions of ethyl (e) at least one selected from corn starch and partially prege latinized starch; cellulose (for example, Aquacoat, FMC). Examples of the 0019. 3 an orally disintegrating tablet according to 1 or water-insoluble acrylic polymer include dispersion liquids of 2, wherein the Sugar or the Sugar alcohol is lactose or ethyl acrylate-methylmethacrylate copolymer (for example, D-mannitol; Eudragit NE30D, Roehm Pharma Gmbh). Among these 0020 4 an orally disintegrating tablet according to 1 or masking agents, the stomach-soluble polymer, capable of 2, wherein the Sugar or the Sugar alcohol is D-mannitol; rapidly dissolving in the stomach, is preferable in terms of 0021 5 an orally disintegrating
Load more

Recommended publications
  • Download Product Catalog
    Total Quality Medications Product Portfolio Rx Product name Dosage form Generic name Pack size Indications A- Alimentary tract and metabolism A02B – Proton pump inhibitor Omecarbex 20 mg H.G Cap Omeprazole +Na 20 Caps Acid reflux and Ulcers Omecarbex 40 mg H.G Cap Carbonate 20 Caps Acid reflux and Ulcers A06A - Laxatives Amiprostone 8 mcg S.G Cap Lubiprostone 20 Capsules Laxative Amiprostone 24 mcg S.G Cap Lubiprostone 10 Capsules Laxative A07A- Intestinal Anti-infective Anti-diarrheal Gastrobiotic 200 mg Tablets Rifiximin 20 Tablets Antidiarrheal Gastrobiotic 550 mg Tablets Rifiximin 30 Tablets Antidiarrheal Nitazode 100 mg/5 ml Suspension Nitazoxanide Bottle 60 ml Antiprotozoal A10B- Oral Anti -diabetics A10-BD - Oral hypoglycemic associations Glimepiride+ Improve glycemic control for type 2 Glimepiride plus 4/30 Tablets 30 Tablets Pioglitazone Hcl diabetes Glimepiride+ Improve glycemic control for type 2 Glimepiride plus 2/30 Tablets 30 Tablets Pioglitazone Hcl diabetes Metformin Hcl + Improve glycemic control for type 2 Bioglitaplus 15/500 Tablets 20 Tablets Pioglitazone Hcl diabetes Metformin Hcl + Improve glycemic control for type 2 Bioglitaplus 15/850 Tablets 20 Tablets Pioglitazone Hcl diabetes A10BX - Other anti diabetics Control the elevation of blood sugar Megy One 10 mg Tablets Mitiglinide 20 Tablets after eating B- Blood and blood forming organs B01A - Anti-thrombotic agents Andorivaban 10 mg F.C Tablets Rivaroxaban 20 Tablets Anticoagulants Andorivaban 15 mg F.C Tablets Rivaroxaban 20 Tablets Anticoagulants Andorivaban 20
    [Show full text]
  • Specifications of Approved Drug Compound Library
    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • Sulfonylurea Stimulation of Insulin Secretion Peter Proks,1 Frank Reimann,2 Nick Green,1 Fiona Gribble,2 and Frances Ashcroft1
    Sulfonylurea Stimulation of Insulin Secretion Peter Proks,1 Frank Reimann,2 Nick Green,1 Fiona Gribble,2 and Frances Ashcroft1 Sulfonylureas are widely used to treat type 2 diabetes smooth, and skeletal muscle, and some brain neurones. In because they stimulate insulin secretion from pancre- all these tissues, opening of KATP channels in response to atic ␤-cells. They primarily act by binding to the SUR metabolic stress leads to inhibition of electrical activity. subunit of the ATP-sensitive potassium (KATP) channel Thus they are involved in the response to both cardiac and and inducing channel closure. However, the channel is cerebral ischemia (2). They are also important in neuronal still able to open to a limited extent when the drug is regulation of glucose homeostasis (3), seizure protection bound, so that high-affinity sulfonylurea inhibition is not complete, even at saturating drug concentrations. (4), and the control of vascular smooth muscle tone (and, thereby, blood pressure) (5). KATP channels are also found in cardiac, skeletal, and smooth muscle, but in these tissues are composed of The KATP channel is a hetero-octameric complex of two different SUR subunits that confer different drug different types of protein subunits: an inwardly rectifying sensitivities. Thus tolbutamide and gliclazide block Kϩ channel, Kir6.x, and a sulfonylurea receptor, SUR (6,7). ␤ ϩ channels containing SUR1 ( -cell type), but not SUR2 Kir6.x belongs to the family of inwardly rectifying K (cardiac, smooth muscle types), whereas glibenclamide, (Kir) channels and assembles as a tetramer to form the glimepiride, repaglinide, and meglitinide block both types of channels.
    [Show full text]
  • Pharmacokinetic and Pharmacodynamic Modeling of Oral
    Liu et al. BMC Pharmacology and Toxicology (2017) 18:54 DOI 10.1186/s40360-017-0161-6 RESEARCH ARTICLE Open Access Pharmacokinetic and pharmacodynamic modeling of oral mitiglinide on glucose lowering in healthy Chinese volunteers Shijia Liu1, Peidong Chen2, Yang Zhao3, Guoliang Dai1, Bingting Sun2, Yao Wang1, Anwei Ding2 and Wenzheng Ju1* Abstract Background: Mitiglinide is a widely used agent for diabetic treatment. We established a pharmacokinetic- pharmacodynamic (PK-PD) model to illustrate the relationship between mitiglinide plasma concentration and its glucose lowering effects in healthy volunteers. Methods: The volunteers participated in the test after the administration of a single dose of 10 mg mitiglinide. The drug concentration in Plasma and the values of glucose levels were determined by LC-MS/MS assay and hexokinase method. A PK-PD model was established with a series of equations to describe the relationship between plasma medicine and glucose, and the equations were solved numerically and fitted to the data with the Phoenix NLME software. Results: The results of the two-compartment model analysis were based on the maximum likelihood criterion and visual inspection of the fittings. The terminal elimination half-life (t1/2) was 1.69 ± 0.16 h and the CL/F was 7.80 ± 1.84 L/h. The plasma glucose levels began to decline by 0.2 h, and hit its bottom decreasing values of 2.6 mg/L at 0.5 h after administration. The calculated parameter and fitting curve indicated that the model established in our experiment fitted well. Conclusions: A PK/PD model illustrates that the relationship between mitiglinide concentration in plasma and glucose lowering effect in healthy volunteers was established.
    [Show full text]
  • Jp Xvii the Japanese Pharmacopoeia
    JP XVII THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION Official from April 1, 2016 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 64 Pursuant to Paragraph 1, Article 41 of the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices (Law No. 145, 1960), the Japanese Pharmacopoeia (Ministerial Notification No. 65, 2011), which has been established as follows*, shall be applied on April 1, 2016. However, in the case of drugs which are listed in the Pharmacopoeia (hereinafter referred to as ``previ- ous Pharmacopoeia'') [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'')] and have been approved as of April 1, 2016 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as of March 31, 2016 as those exempted from marketing approval pursuant to Paragraph 1, Article 14 of the Same Law (hereinafter referred to as ``drugs exempted from approval'')], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on September 30, 2017.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • The Claimed Intermediate Online Database | Drug Names to Search: Control F (PC) Command F (Mac) Open & Search in Ibooks App (Ipad)
    The Claimed Intermediate Online Database | Drug Names www.tcipatent.com To search: Control F (PC) Command F (Mac) Open & search in iBooks app (iPad) Drug Name Abiraterone Acetaminophen Adefovir Dipivoxil Agomelatine Albendazole Alendronic acid Alfentanil Aliskiren Allopurinol Almorexant Almotriptan Alogliptin Alosetron Alprostadil Alvimopan www.tcipatent.com Ambrisentan Aminaphtone Amisulpride Amlodipine Amorolfine Amphetamine Amprenavir Amrubicin Amylmetacresol Anagrelide Anastrozole www.tcipatent.com Apixaban Aprepitant Arformoterol Argatroban Aripiprazole Armodafinil Artemether Artemisinin Asenapine Aspirin Atazanavir www.tcipatent.com Atomoxetine Atorvastatin Atorvastatin ( Rosuvastatin Ezetimibe Linezolid ) Atovaquone Azacitidine Azilsartan Azilsartan medoxomil Azithromycin Baclofen Bazedoxifene Bendamustine www.tcipatent.com Benidipine Betaxolol Bexarotene Biapenem Bicalutamide Bimatoprost Bimatoprost ( Latanoprost Travoprost ) Bisoprolol Bivalirudin Boceprevir Bortezomib www.tcipatent.com Bosentan Brinzolamide Bromfenac Buclizine Buprenorphine Bupropion Cabazitaxel Cabazitaxel ( Docetaxel Paclitaxel ) Candesartan cilexetil Capecitabine Carbabenzpyride Caspofungin Cefamandole www.tcipatent.com Cefdinir Cefditoren pivoxil Cefepime Cefixime Cefoperazone Cefotaxime Cefozopran Cefpodoxime Cefpodoxime proxetil Ceftaroline fosamil Ceftobiprole www.tcipatent.com Ceftobiprole medocaril Ceftriaxone Celecoxib Cetirizine Cevimeline Chloroquine Chlorothiazide Cidofovir Cilastatin Cilazapril Cinacalcet www.tcipatent.com Ciprofloxacin Cisatracurium
    [Show full text]
  • Differences Between Mitiglinide/Voglibose Fixed- Dose
    94 Original Article Differences between Mitiglinide/Voglibose Fixed- dose Combination and Glimepiride in Modifying Low- density Lipoprotein Heterogeneity in Japanese Type-2 Diabetic Patients: A Pilot Study Authors S. Tani1, 2, K. Nagao2, A. Hirayama2 Affiliations 1 Department of Health Planning Center, Nihon University Hospital, Tokyo Japan 2 Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo Japan Key words Abstract nificantly. In the mitiglinide/voglibose group, ●▶ glimepiride ▼ serum LDL-C levels did not change, while sd-LDL ●▶ LDL-heterogeneity Purpose: The purpose of this study was to levels and sd-LDL/LDL-C decreased significantly ●▶ mitiglinide/voglibose ( − 8.6 % and − 7.9 %) and LDL-C/apoB increased ­fixed-dose­combination compare the effects of mitiglinide/voglibose fixed-dose combination and glimepiride on significantly (5.8 %). Fasting blood glucose levels low-density lipoprotein (LDL)-heterogeneity in tended to be reduced to a greater extent in the type-2 diabetic patients with unstable glycemic glimepiride group than in the mitiglinide/voglib- control after treatment with dipeptidyl pepti- ose group ( − 13.9 % vs. − 8.4 %, p = 0.08), while dase-4 (DPP-4) inhibitors. the rate of reduction of HbA1c levels tended Methods: This was an open-label pilot study in to be higher in the mitiglinide/voglibose group which type-2 diabetic patients were randomly than in the glimepiride group ( − 6.9 % vs. − 3.4 %, assigned to the mitiglinide/voglibose (fixed-dose p = 0.09), suggesting differences in fluctuating combination of mitiglinide 10 mg and voglibose blood glucose levels between the 2 groups. 0.2 mg, n = 14) or glimepiride (0.5 mg, n = 16).
    [Show full text]
  • (12) United States Patent (10) Patent N0.: US 7,888,382 B2 Kiyono Et A]
    US007888382B2 (12) United States Patent (10) Patent N0.: US 7,888,382 B2 Kiyono et a]. (45) Date of Patent: Feb. 15, 2011 (54) COMBINED PHARMACEUTICAL 2005/0197376 A1* 9/2005 Kayakiri et al. ........... .. 514/394 PREPARATION FOR TREATMENT OF TYPE 2 DIABETES FOREIGN PATENT DOCUMENTS EP 1 532 979 5/2005 (75) Inventors: Yuji Kiyono, Tokyo (JP); Yoshio JP 2001-316293 11/2001 Okubo, Tokyo (JP); Katsumi Hontani, WO 2007/033292 3/2007 Tokyo (JP); Imao Mikoshiba, Tokyo (JP); Kazuma Ojima, AZumino (JP) OTHER PUBLICATIONS International Search Report issued Jul. 5, 2006 in the International (73) Assignee: Kissei Pharmaceutical Co., Ltd., (PCT) Application of which the present application is the US. Nagano (JP) National Stage. K. Ojima et al., “Pharmacological and Clinical Pro?le of Mitiglinide ( * ) Notice: Subject to any disclaimer, the term of this Calcium Hydrate (Glufast®), A New Insulinotropic Agent With patent is extended or adjusted under 35 Rapid Onset”, Folia Pharmacol. Jpn. (Nippon Yakurigaku Zasshi), 2004, vol. 124, No. 4, pp. 245-255 (English Abstract enclosed). U.S.C. 154(b) by 102 days. K. Ojima et al., “Rapid Onset-Insulinotropic Effect of Mitiglinide Calcium Dihydrate (KAD-1229), A Novel Antipostprandial (21) Appl. No.: 11/918,654 Hyperglycemic Agent”, Jpn. Pharmacol Ther, 2004, vol. 32, No. 2, pp. 73-80. (22) PCT Filed: Apr. 18,2006 R. F. Coniffet al., “Multicenter, Placebo-Controlled Trial Comparing Acarbose (BAY g 5421) With Placebo, Tolbutamide, and (86) PCT No.: PCT/JP2006/308110 Tolbutamide-Plus-Acarbose in Non-Insulin-Dependent Diabetes Mellitus”, The American Journal of Medicine, vol. 98, pp.
    [Show full text]
  • Development and Validation of an LC-MS/MS Method for The
    Printed in the Republic of Korea ANALYTICAL SCIENCE & TECHNOLOGY Vol. 32 No. 2, 35-47, 2019 https://doi.org/10.5806/AST.2019.32.2.35 Development and validation of an LC-MS/MS method for the simultaneous analysis of 26 anti-diabetic drugs in adulterated dietary supplements and its application to a forensic sample Nam Sook Kim†, Geum Joo Yoo†, Kyu Yeon Kim, Ji Hyun Lee, Sung-Kwan Park, Sun Young Baek, and Hoil Kang★ Division of Advanced Analysis, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Osong Health Technology Administration Complex, 187 Osongsaengmyeong2-ro, Osongeup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do 363-700, Korea (Received September 18, 2018; Revised February 21, 2019; Accepted March 7, 2019) Abstract In this study, high-performance liquid chromatography–tandem mass spectrometry (HPLC-MS/ MS) was employed to detect 26 antidiabetic compounds in adulterated dietary supplements using a simple, selective method. The work presented herein may help prevent incidents related to food adulteration and restrict the illegal food market. The best separation was obtained on a Shiseido Capcell Pak® C18 MG- II (2.0 mm × 100 mm, 3 µm), which improved the peak shape and MS detection sensitivity of the target compounds. A gradient elution system composed of 0.1 % (v/v) formic acid in distilled water and methanol at a flow rate of 0.3 mL/min for 18 min was utilized. A triple quadrupole mass spectrometer with an electrospray ionization source operated in the positive or negative mode was employed as the detector. The developed method was validated as follows: specificity was confirmed in the multiple reaction monitoring mode using the precursor and product ion pairs.
    [Show full text]